Pietro Taverna

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Jean‐Pierre J. Issa, Gail J. Roboz, David A. Rizzieri et al. · The Lancet Oncology · 2015 · 280 citations · Full text

Hematological Malignancy, Dose-escalation Phase 1, Oncology +9

Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.

Lili Liu, Pietro Taverna, Cecilia M. Whitacre et al. · PubMed · 1999 · 163 citations

Epigenetic Change, Pathology, Molecular Biology +22

Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia

Lisa S. Chen, Sanjeev Redkar, Pietro Taverna et al. · Blood · 2011 · 160 citations · Full text

Generation of an endogenous DNA-methylating agent by nitrosation in Escherichia coli

Pietro Taverna, Barbara Sedgwick · Journal of Bacteriology · 1996 · 158 citations · Full text

Engineering, Dna Methylation, Molecular Biology +18

Epigenetic Targeting of Ovarian Cancer Stem Cells

Yinu Wang, Horacio Cárdenas, Fang Fang et al. · Cancer Research · 2014 · 158 citations · Full text

Epigenetic Change, Dna Methylation, Ocsc Growth +16